Olumiant (Baricitinib) Tablet

Description

Description

This page contains brief details about the drug baricitinib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Baricitinib was initially approved by the United States Food and Drug Administration (FDA) on May 31, 2018.

Mechanism of Action of Baricitinib

Baricitinib is a Janus kinase (JAK) inhibitor, targeting JAK1 and JAK2 enzymes. These enzymes are integral to intracellular signaling pathways involved in immune responses and inflammation. By inhibiting JAK1 and JAK2, it interferes with transmitting signals that contribute to the activation of immune cells and the production of inflammatory molecules. This modulation of signaling pathways leads to a dampened immune response and reduced inflammation, effectively managing autoimmune conditions like rheumatoid arthritis.

Uses of Baricitinib

Baricitinib is primarily indicated for treating moderate to severe rheumatoid arthritis in adults who have not adequately responded to conventional disease-modifying antirheumatic drugs (DMARDs). It is employed to alleviate inflammation and manage autoimmune conditions. Additionally, its potential applications extend to other autoimmune disorders and inflammatory conditions.

Baricitinib Dosage available

Baricitinib is typically administered orally, which means it is taken by mouth as tablets. It is available as an oral tablet for easy ingestion. Your healthcare provider will determine the specific dosage and frequency of administration based on your medical condition and individual needs.